PDT reduces choroidal thickness

Article

Low-fluence photodynamic therapy (PDT) decreases subfoveal choroidal thickness (SFCT) in central serous chorioretinopathy (CSC), states a paper in the journal Eye.

Low-fluence photodynamic therapy (PDT) decreases subfoveal choroidal thickness (SFCT) in central serous chorioretinopathy (CSC), states a paper in the journal Eye.

Dr N.H. Kang et al., Department of Ophthalmology, Ewha Womans University, School of Medicine, Mok-dong Hospital, Seoul, Republic of Korea, conducted a retrospective study on 36 consecutive eyes of 36 patients. Of the eyes included in the investigation, there were 16 with spontaneously resolved CSC and 20 eyes with PDT-treated CSC. At each visit BCVA and SFCT were evaluated until complete absorption of the retinal fluid. There was also a control group that consisted of 32 normal subjects.

Baseline SFCT was 459.16±77.50 μm and decreased to 419.31±54.49μm after a spontaneous resolution. SFCT in the PDT group was 416.43±74.01 and 349.50±88.99 μm at baseline and after spontaneous resolution, respectively.

Patients with CSC decreased after both spontaneous resolution and low-fluence PDT. However, only the PDT group experienced a decrease comparable to that of the control subjects.

The abstract can be read here.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.